| Bioactivity | Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Odiparcil (SB-424323) is indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II) [1][2]. | ||||||||||||
| Target | Thrombin | ||||||||||||
| Name | Odiparcil | ||||||||||||
| CAS | 137215-12-4 | ||||||||||||
| Formula | C15H16O6S | ||||||||||||
| Molar Mass | 324.35 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Myers AL, et al. Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparin. J Clin Pharmacol. 2008 Oct;48(10):1158-70 [2]. Levy JH, et al. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology. 2010 Sep;113(3):726-45. |